Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology Vol. 20; no. 3; pp. 371 - 382
Main Authors: Loi, Sherene, Giobbie-Hurder, Anita, Gombos, Andrea, Bachelot, Thomas, Hui, Rina, Curigliano, Giuseppe, Campone, Mario, Biganzoli, Laura, Bonnefoi, Hervé, Jerusalem, Guy, Bartsch, Rupert, Rabaglio-Poretti, Manuela, Kammler, Roswitha, Maibach, Rudolf, Smyth, Mark J, Di Leo, Angelo, Colleoni, Marco, Viale, Giuseppe, Regan, Meredith M, André, Fabrice, Fumagalli, Debora, Gelber, Richard D, Goulioti, Theodora, Hiltbrunner, Anita, Hui, Rita, Roschitzki, Heidi, Ruepp, Barbara, Boyle, Fran, Stahel, Rolf, Aebi, Stefan, Coates, Alan S, Goldhirsch, Aron, Karlsson, Per, Kössler, Ingrid, Fournarakou, Stamatina, Gasca, Adriana, Pfister, Rita, Ribeli-Hofmann, Sabrina, Weber, Magdelena, Celotto, Daniela, Comune, Carmen, Frapolli, Michela, Sánchez-Hohl, Magdalena, Huang, Hui, Mahoney, Caitlin, Price, Karen, Scott, Karolyn, Shaw, Holly, Fischer, Susan, Greco, Monica, King, Colleen, Andrighetto, Stefania, Piccart-Gebhart, Martine, Findlay, Heather, Jenkins, Michelle, Karantza, Vassiliki, Mejia, Jaime, Schneier, Patrick
Format: Journal Article Web Resource
Language:English
Published: England Elsevier Ltd 01-03-2019
Elsevier Limited
Lancet Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first